Adicet Bio Updates Corporate Address, Phone in 8-K Filing

TL;DR

**Adicet Bio just filed an 8-K updating its official address and phone number.**

AI Summary

Adicet Bio, Inc. filed an 8-K on January 4, 2024, to update its corporate information, including its business address to 200 Berkeley Street, 19th Floor, Boston, Massachusetts, 02116, and its telephone number to (650) 503-9095. This filing also confirms its trading symbol as ACET on The Nasdaq Global Market. For investors, this matters as it provides current contact and operational details, ensuring transparency and up-to-date corporate information for a company whose stock they own or are considering buying.

Why It Matters

This filing provides updated contact information and confirms the company's listing on The Nasdaq Global Market, which is essential for investor communication and regulatory compliance.

Risk Assessment

Risk Level: low — This filing is purely administrative, updating contact information, and does not indicate any operational or financial risks.

Analyst Insight

Investors should update their records with the new contact information for Adicet Bio, Inc. and note the confirmation of its Nasdaq listing, but this filing alone does not warrant any immediate trading action.

Key Numbers

• (650) 503-9095 — Registrant's Telephone Number (new primary contact number for Adicet Bio, Inc.)
• 200 Berkeley Street, 19th Floor — Business Address (new principal executive offices street and floor)
• 02116 — Zip Code (zip code for the new business address)
• January 04, 2024 — Date of Report (date of the earliest event reported in the filing)
• $0.0001 — par value per share (par value of the Common Stock)

Key Players & Entities

• Adicet Bio, Inc. (company) — the registrant filing the 8-K
• Boston, Massachusetts (location) — new principal executive offices city and state
• 001-38359 (other) — Commission File Number
• 81-3305277 (other) — IRS Employer Identification No.
• ACET (other) — trading symbol for Common Stock
• The Nasdaq Global Market (other) — exchange where securities are registered

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Global Ma

Filing Documents

• acet-20240104.htm (8-K) — 56KB
• acet-ex99_1.htm (EX-99.1) — 31KB
• acet-ex99_2.htm (EX-99.2) — 1KB
• img94724212_0.jpg (GRAPHIC) — 2KB
• acet-ex99_2s1.jpg (GRAPHIC) — 296KB
• 0000950170-24-001490.txt ( ) — 624KB
• acet-20240104.xsd (EX-101.SCH) — 2KB
• acet-20240104_pre.xml (EX-101.PRE) — 10KB
• acet-20240104_lab.xml (EX-101.LAB) — 13KB
• acet-20240104_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 4, 2024, Adicet Bio, Inc. (Adicet or the Company) issued a press release titled “Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024,” a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On January 4, 2024, the Company provided the following program updates and milestones for 2024: ADI-001 Autoimmune diseases • Investigational New Drug application (IND) cleared for lupus nephritis. In December 2023, the U.S. Food and Drug Administration (FDA) cleared Adicet’s IND application for ADI-001 in lupus nephritis. • Initiate Phase 1 clinical trial of ADI-001 for the treatment of lupus nephritis in the second quarter of 2024 . The Company plans to initiate a Phase 1 clinical trial to assess the safety and efficacy of ADI-001 in lupus nephritis and may provide a clinical update from the trial in the second half of 2024. Adicet expects to expand into additional autoimmune indications in the near future. Hematologic malignancies • Focus enrollment on mantle cell lymphoma (MCL) patients in ongoing Phase 1 GLEAN study. Adicet will focus on the MCL patient population in the ongoing Phase 1 GLEAN study (at dose level 4), which experienced the greatest clinical benefit in the June 2023 update. While these were early data, an 80% CR rate and 60% 6-month CR rate in late line MCL patients were reported in the June 2023 clinical update, Cmax and exposure by area under the curve (AUC) exceeded that of approved autologous CD19 CAR T therapies, and a favorable safety profile was observed with no significant risk of cytokine release syndrome, immune effector cell associated neurotoxicity syndrome or T-cell malignancies. These initial clinical results, coupled with the potential to dose off-the-shelf in a community setting, support ADI-001 as a potentially attractive therapy for MCL patients. The Company is evaluating the option of advancing ADI-001 to a potentially pivotal study in MCL patients under an accelerated approval pathway. • The Company remains on track to provide an ADI-001 clinical update in the second half of 2024. ADI-270 Renal cell carcinoma • Plan to file IND for ADI-270

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Adicet Bio, Inc. on January 4, 2024, furnished herewith. 99.2 Adicet Bio, Inc. pipeline chart as of January 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADICET BIO, INC. Date: January 4, 2024 By: /s/ Nick Harvey Name: Title: Nick Harvey Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR